GenomedWAR:GEN -6.11%83 EV-to-FCF is 14.21 as of Jul. 02, 2026, which is 23% below its 10-year median of 18.43. GuruFocus rates WAR:GEN with a GF Score™ of 83/100 and a GF Value™ of zł37.85 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 97 Medical Diagnostics & Research companies, Genomed ranks better than 65.98% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Genomed's Enterprise Value is zł26.40 Mil.
Genomed's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was zł1.86 Mil. Therefore, Genomed's EV-to-FCF for today is 14.21.
The historical rank and industry rank for Genomed's EV-to-FCF or its related term are showing as below:
WAR:GEN'
s EV-to-FCF Range Over the Past 10 Years
Min: -1131.1 Med: 18.43 Max: 1088.51
Current: 15.06
During the past 13 years, the highest EV-to-FCF of Genomed was 1088.51. The lowest was -1131.10. And the median was 18.43.
WAR:GEN's EV-to-FCF is ranked better than 65.98% of 97
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.85
vs WAR:GEN: 15.06
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Genomed's share price for today is zł24.60.
Genomed's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł2.385.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Genomed EV-to-FCF Related Terms
Genomed EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Genomed's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Genomed's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomed EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genomed's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Genomed's EV-to-FCF falls into.
Genomed's current Enterprise Value is zł26.40 Mil.
Genomed's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł1.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomed (WAR:GEN) has a EV-to-FCF of 14.21 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Genomed and its competitors. This is 23% below median its historical median of 18.43. According to the industry distribution chart, Genomed ranks #33 out of 97 companies in the Medical Diagnostics & Research industry, placing it in the top 34%.
Is Genomed's EV-to-FCF too high?
Genomed's current EV-to-FCF of 14.21 is 23% below median its 10-year median of 18.43. The Medical Diagnostics & Research industry median EV-to-FCF is 22.85. Genomed's value of 14.21 is 37.8% below this industry median. Based on the distribution chart, Genomed ranks #33 out of 97 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Genomed has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomed's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genomed ranks #33 out of 97 companies for EV-to-FCF. This puts Genomed in the upper half of its industry. The industry median EV-to-FCF is 22.85. Genomed's value of 14.21 is 37.8% below this benchmark. While the company's 10-year median is 18.43 vs. the industry median of 22.85, Genomed has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 22.85, based on 97 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomed's current EV-to-FCF of 14.21 is 37.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Genomed and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 22.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomed's current EV-to-FCF is 14.21, which is 23% below median its own 10-year median of 18.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomed stock overvalued right now?
Based on GuruFocus' analysis, Genomed (WAR:GEN) is currently considered Significantly Undervalued. The stock's GF Value™ is zł37.85, compared to a current price of zł24.60 — trading 35% below its estimated fair value. The current EV-to-FCF is 14.21, which is 23% below median its 10-year median of 18.43 and 37.8% below the Medical Diagnostics & Research industry median of 22.85. Genomed's overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Genomed (WAR:GEN), the current EV-to-FCF is 14.21 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomed (WAR:GEN) Overvalued in 2026?
Based on GuruFocus' analysis, Genomed stock appears to be undervalued.
The current stock price of zł24.60 is trading 35% below its estimated GF Value™ of zł37.85.
GuruFocus considers Genomed to be Significantly Undervalued.
Key valuation signals for WAR:GEN:
EV-to-FCF: 14.21 (23% below median its 10-year median of 18.43)
GF Value™: zł37.85 vs. price of zł24.60 (35% below fair value)
Industry Position: 37.8% below the Medical Diagnostics & Research median (#33 of 97)
No single metric tells the full story. See the WAR:GEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomed SA assembles outstanding molecular biologists and genetic diagnosticians. The company provides diagnostic service that comprises DNA analysis and congenital diseases diagnostics based on DNA sequencing. It offers Diagnostic service and Service for scientific purposes.
83GF Score
Get the complete analysis for WAR:GEN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:GEN has been successfully added to your 
